benzbromarone has been researched along with allopurinol in 145 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (26.21) | 18.7374 |
| 1990's | 16 (11.03) | 18.2507 |
| 2000's | 23 (15.86) | 29.6817 |
| 2010's | 52 (35.86) | 24.3611 |
| 2020's | 16 (11.03) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Ao, GZ; Hu, QH; Li, HQ; Li, SN; Li, YY; Wan, QW; Wang, HN; Zhou, MZ | 1 |
| Fu, P; Li, X; Liu, J; Ma, L | 1 |
| Mertz, DP | 5 |
| Flury, W; Montandon, A; Ruch, HR | 1 |
| Avery, GS; Brogden, RN; Heel, RC; Speight, TM | 1 |
| Arntz, HR; Dreykluft, HR; Leonhardt, H | 1 |
| König, HJ | 1 |
| Barsom, S | 1 |
| Göhmann, E; Mertz, DP | 1 |
| Flügel, M; Geldmacher, J | 1 |
| Akaoka, I; Masuda, T; Nishida, Y; Nishizawa, T | 1 |
| Fox, IH; Sinclair, DS | 1 |
| Terhorst, B | 1 |
| Berg, G; Matzkies, F | 1 |
| Klein, G; Rainer, F; Wottawa, A | 1 |
| Siegenthaler-Zuber, G | 1 |
| Matzkies, F | 3 |
| Bargnoux, H; Berger, JA; Bussiere, JL; Chabard, JL; Lartigue-Mattei, C; Petit, J; Ristori, JM | 1 |
| Akaoka, I; Fujimori, S; Kaneko, K | 1 |
| Berg, H | 1 |
| Akiyama, T; Ikegami, M; Imanishi, M; Ishii, T; Kanda, H; Kunikata, S; Kurita, T; Matsuura, T; Nishioka, T; Uemura, T | 1 |
| Akaoka, I; Fujimori, S; Ishizuka, I; Kaneko, K | 1 |
| Clavel, JP; Colin, JN; Farinotti, R; Fredj, G; Nebout, T | 1 |
| Buisse, JM; Demarez, JP | 1 |
| Cabo, J; Gomez-Ruiz, MD; Izquierdo, R; Rodilla, F; Sanchez-Beltran, MJ | 2 |
| Hesse, A; Schneeberger, W; Vahlensieck, W | 1 |
| Clavel, JP; Colin, JN; Dietlin, F; Farinotti, R; Fredj, G; Tod, M; Vignon, E | 1 |
| Eichhorn, R; Mertz, DP | 1 |
| Borner, K; Mertz, DP | 1 |
| Gröbner, W; Löffler, W; Zöllner, N | 1 |
| Rodnan, GP | 1 |
| Henkel, E; Mitzkat, HJ; Rüffer, C; Zorn, G | 1 |
| Burck, G; Dauterstedt, W; Heidelmann, G; Heinrich, JJ; Ohlmer, R | 1 |
| Schepers, GW | 1 |
| Dorn, M | 1 |
| Breithaupt, B; Tittel, M | 1 |
| Mascher, H; Nitsche, V | 1 |
| Sailer, D | 1 |
| Akaoka, I; Fujimori, S; Kaneko, K; Yamanaka, H | 1 |
| Balkarov, IM | 1 |
| Groenewoud, G; Hundt, HK; Müller, FO; Schall, R; van der Merwe, JC; van Dyk, M | 1 |
| Goriki, K; Ochiai, M; Okusaki, K; Takahashi, H; Toda, K; Tokunou, H; Uehara, S | 1 |
| Hirai, A; Saito, Y | 1 |
| Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamakita, J; Yamamoto, T | 2 |
| Grahame, R; Marsh, FP; McBride, MB; Simmonds, HA | 1 |
| Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E | 1 |
| Chazerain, P; Ziza, JM | 1 |
| Calabozo, M; García-Erauskin, G; Herrero-Beites, AM; Perez-Ruiz, F; Pijoan, JI | 1 |
| Gröbner, W; Walter-Sack, I | 1 |
| Gorter, KJ; Romeijnders, AC | 1 |
| Akkasilpa, S; Deesomchok, U; Hanvivadhanakul, P | 1 |
| Calabozo, M; Herrero-Beites, AM; Perez-Ruiz, F; Pijoan, JI; Ruibal, A | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C | 1 |
| Yamanaka, H | 1 |
| Murakami, H; Shimamoto, K | 1 |
| Baum, U; Boxberger, F; Brueckl, WM; Hahn, EG; Harsch, IA; Hautmann, M; Wein, A | 1 |
| Ito, T; Kamatani, N; Kato, Y; Nakajima, A; Yamanaka, H | 1 |
| Akkasilpa, S; Avihingsanon, Y; Deesomchok, U; Osiri, M | 1 |
| Gow, P; Kumar, S; Ng, J | 1 |
| Wong, ML | 1 |
| Atxotegi, J; Calabozo, M; Hernando, I; Nolla, JM; Perez-Ruiz, F | 1 |
| Caldas, CA; Fuller, R | 1 |
| Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN | 1 |
| Brouwers, JR; Delsing, J; Griep, EN; Hoekstra, M; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN | 1 |
| Fujimori, S | 1 |
| Ohno, I | 1 |
| Gomi, H; Hikita, M; Hosoya, T; Ichida, K; Ohno, I; Okabe, H; Saikawa, H; Uetake, D; Yamaguchi, Y | 1 |
| Li, BH; Wang, YF; Xu, WB; Zhang, M; Zhou, M; Zhou, R | 1 |
| Brouwers, JR; Delsing, J; Haagsma, C; Jansen, TL; Reinders, MK; van de Laar, MA; van Roon, EN | 1 |
| Inokuchi, T; Ka, T; Masuzaki, H; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, A; Yamamoto, T | 1 |
| Anker, SD; Doehner, W; Furuse, Y; Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugasa, Y; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C | 1 |
| Gonzalez-Gay, MA; Hernandez-Baldizon, S; Herrero-Beites, AM; Perez-Ruiz, F | 1 |
| Dalbeth, N; Doyle, A; McQueen, FM | 1 |
| Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF | 1 |
| Taniguchi, A | 1 |
| Kriegsmann, J; Lange, U; Müller-Ladner, U; Panzner, I; Tausche, AK | 1 |
| Hara, I; Kohjimoto, Y; Sasaki, Y | 1 |
| Johnson, RJ; Mazali, FC; Mazzali, M | 1 |
| Dong, L; Huang, X; Pang, M; Wang, S; Zhou, L; Zhu, W | 1 |
| de Miguel, E; Mejía-Chew, C; Puig, JG; Torres, RJ | 1 |
| Chen, GL; Li, L; Na, S; Zhu, LR | 1 |
| Chao, PH; Cheng, CL; Hsu, JC; On, AW; Weng, MM; Yang, YH | 1 |
| Aoki, T; Hishida, M; Maekawa, M; Morinaga, T; Tamai, H; Tomida, H | 1 |
| Becker, MA; Chaichian, Y; Chohan, S | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R | 2 |
| Chen, H; Ji, Z; Jiang, L; Ma, L; Wei, L; Yu, Q; Zhang, Z | 1 |
| Akahoshi, Y; Ikeda, M; Shinozuka, K; Tabuchi, M; Uchida, S; Wakuda, H; Yamada, S | 1 |
| Dalbeth, N; Robinson, PC | 1 |
| Hanvivadhanakul, P; Wongdet, R | 1 |
| Gui, D; Guo, Y; Jiang, Q; Wang, N | 1 |
| Füeßl, HS; Stiefelhagen, P | 1 |
| Chen, G; Jia, P | 1 |
| Cathro, A; Corkill, M; Dalbeth, N; Frampton, C; Gardner, D; Grainger, R; Haslett, J; Kain, T; Kumar, R; Kumar, S; Metcalfe, S; Porter, D; Stamp, LK; Stebbings, S; Taylor, G; White, D; Wyeth, J | 1 |
| Hifumi, A; Kojima, S; Ogawa, H; Soejima, H | 1 |
| Stamp, LK | 1 |
| Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J | 1 |
| Chiang, SJ; Daimon, M; Ho, Y; Lin, HC; Uang, YS; Wang, CH; Wang, LH | 1 |
| Kim, JW; Kwak, SG; Park, SH | 1 |
| Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC | 1 |
| Janssen, CA; Krol, M; Oude Voshaar, MAH; van de Laar, MAFJ; Vonkeman, HE | 1 |
| Jansen, TL; Perez-Ruiz, F; Richette, P; Tausche, AK | 1 |
| Chang, HW; Lan, YC; Lin, MH; Lin, YW; Wang, RY | 1 |
| Deng, X; Li, J; Liu, H; Qi, Y; Xiong, B; Zhang, Y | 1 |
| Bachettoni, A; Bartoli, M; Facchiano, F; Gutsaeva, DR; Malla, P; Martin, PM; Montemari, A; Powell, FL; Repossi, A; Ripandelli, G; Tawfik, A; Thounaojam, MC | 1 |
| Li, YJ; Perng, WT; Tseng, KY; Wang, YH; Wei, JC | 1 |
| Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP | 1 |
| Araujo, E; Baraf, HSB; Bayat, S; Cavallaro, A; Ellmann, H; Kleyer, A; Lell, M; Manger, B; Rech, J; Schenker, H; Schett, G; Simon, D; Tascilar, K | 1 |
| Chen, JS; Chiou, MJ; Chung, TT; Hsieh, AH; Kuo, CF; Lan, WC; Luo, SF; Tseng, WY; Wang, LC; Yu, KH | 1 |
| Lin, X; Tang, F; Xu, J; Zhang, JX | 1 |
| Hosoyamada, M; Kimura, Y; Kono, H; Onda, A; Tsukui, D; Yanagida, T | 1 |
| Sakaguchi, S | 1 |
| Doi, Y; Fukae, S; Ikeda, S; Kawano, H; Koga, S; Maemura, K; Minami, T; Nakata, T; Tsuneto, A; Yonekura, T | 1 |
| Borghi, C; Cicero, AFG; Fogacci, F; Kuwabara, M | 1 |
| Essam, HM; Mohamed, HM | 1 |
| Becce, F; Budzik, JF; Ducoulombier, V; Lefebvre, A; Pascart, T | 1 |
| Abdel-Khalek, MM; Abdelhamid, AG; Belal, TS; El-Kafrawy, DS | 1 |
| Kang, EH; Kim, SC; Park, EH; Shin, A; Song, JS | 1 |
| Cai, M; Chen, S; Gao, X; Hu, H; Huang, L; Li, X; Liang, D; Liu, Y; Wu, Q; Xiao, C; Xie, Y; Yong, T | 1 |
| Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X | 1 |
| Chang, HH; Hsieh, SM; Lin, DP; Pai, HL; Su, YS; Sue, XY | 1 |
| Iguchi, T; Ishiguro, C; Kajiyama, K; Kimura, R; Nakazato, Y; Oniyama, Y; Sawada, S; Shida, H; Uyama, Y | 1 |
| Kawada, T | 1 |
| Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS | 1 |
20 review(s) available for benzbromarone and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
Topics: Aspirin; Benzbromarone; Benzofurans; Drug Interactions; Fasting; Gout; Humans; Kidney Diseases; Kinetics; Lipid Metabolism; Pyrazinamide; Triglycerides; Uric Acid; Xanthine Oxidase | 1977 |
Treatment of the gout and other forms of crystal-induced arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Benzbromarone; Colchicine; Gout; Gout Suppressants; Humans; Indomethacin; Kidney; Phenylbutazone; Probenecid; Sulfinpyrazone; Uric Acid | 1982 |
[Management of hyperuricemia in diabetes].
Topics: Allopurinol; Benzbromarone; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Humans; Insulin Resistance; Probenecid; Uric Acid; Uricosuric Agents | 1997 |
[Anti hyperuricemic agents].
Topics: Allopurinol; Benzbromarone; Humans; Hyperuricemia; Uricosuric Agents | 2003 |
[Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Kidney Diseases; Probenecid; Prognosis; Risk; Uricosuric Agents; Urinary Calculi; Xanthine Oxidase | 2003 |
[Essential hypertension].
Topics: Allopurinol; Antihypertensive Agents; Benzbromarone; Cerebrovascular Disorders; Humans; Hypertension; Hyperuricemia; Insulin Resistance; Myocardial Ischemia; Uricosuric Agents | 2003 |
[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Patient Care Planning; Practice Guidelines as Topic; Renal Insufficiency; Uric Acid | 2008 |
[Uricosuric agent].
Topics: Allopurinol; Benzbromarone; Gout; Humans; Hyperuricemia; Kidney Tubules, Proximal; Organic Anion Transporters; Organic Cation Transport Proteins; Uric Acid; Uricosuric Agents | 2008 |
[Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Glucocorticoids; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Metabolic Syndrome; Practice Guidelines as Topic; Probenecid; Uricosuric Agents | 2010 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Inflammasomes; Interleukin-1; Long-Term Care; Probenecid; Signal Transduction; Thiazoles; Uric Acid | 2011 |
[Clinical strategies for prevention of drug-induced urinary calculi].
Topics: Allopurinol; Anti-Bacterial Agents; Ascorbic Acid; Benzbromarone; Calcium; Calcium Compounds; Carbonic Anhydrase Inhibitors; Crystallization; Diuretics; Drug Combinations; Furosemide; Glucocorticoids; Humans; Magnesium Silicates; Oxalates; Protease Inhibitors; Purines; Time Factors; Triamterene; Urinary Calculi; Vitamin D | 2011 |
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Risk Reduction Behavior; Thiazoles; Urate Oxidase; Uricosuric Agents | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2014 |
Uricosuric medications for chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Controlled Clinical Trials as Topic; Female; Gout; Humans; Male; Middle Aged; Probenecid; Randomized Controlled Trials as Topic; Uric Acid; Uricosuric Agents | 2014 |
Advances in pharmacotherapy for the treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzbromarone; Clinical Trials, Phase III as Topic; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Probenecid; Thiazoles; Urate Oxidase; Uric Acid | 2015 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care Planning; Probenecid; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2017 |
International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
Topics: Benzbromarone; Europe; Febuxostat; Gout; Humans; International Cooperation; Practice Guidelines as Topic; Probenecid; Rheumatology; Thioglycolates; Triazoles; Uricosuric Agents; Xanthine Oxidase | 2018 |
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Naphthalenes; Nitriles; Phenylacetates; Polyethylene Glycols; Probenecid; Propionates; Pyridines; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2021 |
28 trial(s) available for benzbromarone and allopurinol
| Article | Year |
|---|---|
[Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Female; Humans; Male; Middle Aged; Uric Acid | 1979 |
[Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Humans; Hyperlipidemias; Male; Middle Aged; Triglycerides; Uric Acid | 1979 |
[Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Drug Combinations; Female; Gout; Humans; Male; Metabolic Clearance Rate; Middle Aged; Uric Acid | 1976 |
[Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Calcium; Citrates; Creatinine; Glomerular Filtration Rate; Gout; Humans; Magnesium; Male; Middle Aged; Natriuresis; Sodium; Uric Acid | 1977 |
[Effectiveness and tolerance of long-term uricosuric treatment].
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Combinations; Female; Gout; Humans; Kidney Calculi; Male; Middle Aged; Uric Acid | 1990 |
[Pharmacokinetic interaction between the active metabolite of allopurinol and benzbromarone].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Interactions; Humans; Kinetics | 1986 |
[Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gout; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oxypurinol; Purines; Pyrimidines | 1983 |
Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Female; Humans; Male; Placebos; Probenecid; Uric Acid | 1981 |
[The effect on uric acid and other laboratory parameters. A long-term study].
Topics: Allopurinol; Benzbromarone; Benzofurans; Clinical Trials as Topic; Gout; Humans; Uric Acid | 1982 |
Effect of hypouricemic agents on serum carbohydrate-deficient transferrin in gouty patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Allopurinol; Benzbromarone; Chromatography, Ion Exchange; Drug Therapy, Combination; Gout; Humans; Isoelectric Focusing; Male; Middle Aged; Oxypurinol; Probenecid; Radioimmunoassay; Transferrin | 1994 |
The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Gout; Humans; Male; Middle Aged; Oxypurinol; Uric Acid | 1993 |
Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Topics: Adult; Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Gout; Gout Suppressants; Humans; Male; Middle Aged; Purines; Pyrimidines; Time Factors; Uric Acid; Uricosuric Agents; Uridine; Xanthine Oxidase | 1997 |
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Drug Administration Schedule; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Uric Acid; Uricosuric Agents | 1998 |
Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Creatinine; Drug Therapy, Combination; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Risk Factors; Uric Acid; Uricosuric Agents | 2000 |
Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gout; Humans; Male; Middle Aged; Probability; Statistics, Nonparametric; Treatment Outcome; Uric Acid; Uricosuric Agents; Urinalysis | 2002 |
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Crystallization; Drug Therapy, Combination; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Uric Acid | 2002 |
Benzbromarone therapy in management of refractory gout.
Topics: Adult; Allopurinol; Benzbromarone; Creatinine; Female; Gout; Humans; Incidence; Male; Metabolic Clearance Rate; Middle Aged; New Zealand; Treatment Outcome; Uric Acid | 2005 |
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; Uric Acid; Uricosuric Agents | 2007 |
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Probenecid; Prospective Studies; Treatment Failure; Uric Acid | 2009 |
[Stage-based treatment of gouty arthritis by combination therapy of traditional Chinese and Western medicines: a randomized controlled trial].
Topics: Adolescent; Adult; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Diclofenac; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Gout Suppressants; Humans; Male; Middle Aged; Phytotherapy; Treatment Outcome; Young Adult | 2008 |
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Topics: Aged; Allopurinol; Benzbromarone; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Oxypurinol; Patient Compliance; Prospective Studies; Treatment Outcome; Uric Acid; Uricosuric Agents | 2009 |
Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
Topics: 3T3-L1 Cells; Adiponectin; Adult; Allopurinol; Animals; Benzbromarone; Gene Expression; Gout; Humans; Male; Mice; Middle Aged; PPAR gamma | 2009 |
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Topics: Aged; Benzbromarone; Double-Blind Method; Female; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Up-Regulation; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2010 |
Utilization patterns of antihyperuricemic agents following safety announcement on allopurinol and benzbromarone by Taiwan Food and Drug Administration.
Topics: Allopurinol; Benzbromarone; Cohort Studies; Drug Labeling; Drug Utilization; Gout Suppressants; Humans; Hyperuricemia; Longitudinal Studies; National Health Programs; Taiwan | 2014 |
Therapeutic strategy for efficient reduction of serum uric acid levels with allopurinol versus benzbromarone in hyperuricemic patients with essential hypertension - A randomized crossover study (terao study).
Topics: Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Drug Administration Schedule; Drug Monitoring; Enzyme Inhibitors; Essential Hypertension; Female; Humans; Hypertension; Hyperuricemia; Kidney Function Tests; Male; Middle Aged; Organic Anion Transporters; Stroke Volume; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2016 |
Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Topics: Allopurinol; Benzbromarone; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Population Surveillance; Risk Factors; Taiwan; Treatment Outcome; Uric Acid; Uricosuric Agents | 2017 |
Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Topics: Adiponectin; Aged; Arginine; Benzbromarone; Cross-Over Studies; Endothelium, Vascular; Febuxostat; Female; Gout Suppressants; Humans; Hyperemia; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Treatment Outcome; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2020 |
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospective Studies; Treatment Outcome; Uric Acid | 2022 |
97 other study(ies) available for benzbromarone and allopurinol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents.
Topics: Animals; Curcumin; Enzyme Inhibitors; HEK293 Cells; Humans; Hyperuricemia; Male; Mice; Models, Molecular; Organic Anion Transporters; Organic Cation Transport Proteins; Uric Acid; Xanthine Oxidase | 2017 |
[The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Dosage Forms; Female; Humans; Male; Middle Aged; Uric Acid; Uricosuric Agents | 1978 |
[The treatment of hyperuricemia after kidney transplantation].
Topics: Allopurinol; Azathioprine; Benzbromarone; Creatinine; Drug Interactions; Female; Humans; Kidney Transplantation; Male; Transplantation, Homologous; Uric Acid; Urinary Calculi | 1977 |
[Therapy of gout].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Colchicine; Gout; Humans; Immobilization; Indomethacin; Uric Acid | 1979 |
[Allomaron in hyperuricemia and gout].
Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Drug Evaluation; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1979 |
[Allopurinol-benzbromarone combination. Renal excretion of various ions during high-dosage therapy using an allopurinol-benzbromarone combination].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Humans; Ions; Kidney; Male; Urodynamics | 1978 |
[Gout - a surgical problem].
Topics: Allopurinol; Benzbromarone; Female; Gout; Hand; Humans; Middle Aged; Patient Care Team; Uric Acid | 1978 |
Treatment of gout with alternate-day hypo-uricaemic drugs.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Female; Gout; Humans; Male; Middle Aged; Sulfinpyrazone; Uric Acid | 1978 |
The pharmacology of the hypouricemic effect of benzbromarone.
Topics: Aspirin; Benzbromarone; Benzofurans; Blood Proteins; Drug Interactions; Glomerular Filtration Rate; Kidney Tubules; Protein Binding; Pyrazinamide; Sulfinpyrazone; Uric Acid; Xanthine Oxidase | 1977 |
[Possibilities of drug prevention of calculi].
Topics: Allopurinol; Aluminum Hydroxide; Benzbromarone; Humans; Kidney Calculi; Penicillamine | 1977 |
[Isolated or combined drug therapy of hyperuricemia?].
Topics: Allopurinol; Benzbromarone; Drug Therapy, Combination; Gout; Humans; Uric Acid; Uricosuric Agents | 1977 |
[Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Gout; Humans; Time Factors; Uric Acid | 1976 |
[The effect of uricosuric and uricostatic drugs on DNA metabolism].
Topics: Allopurinol; Benzbromarone; Cells, Cultured; DNA; Gout Suppressants; Oxypurinol; Radiation, Ionizing; Thymidine; Ultraviolet Rays; Uricosuric Agents | 1976 |
[Which uric acid value is in need of treatment?].
Topics: Allopurinol; Benzbromarone; Citrates; Coronary Disease; Gout; Humans; Hyperlipidemias; Hypertension; Hypoxanthine Phosphoribosyltransferase; Kidney Diseases; Lesch-Nyhan Syndrome; Obesity; Uric Acid | 1976 |
[Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gout; Humans; Male; Uric Acid | 1992 |
Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry.
Topics: Adult; Allopurinol; Benzbromarone; Drug Combinations; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Hypoxanthines; Male; Models, Biological; Oxypurinol; Xanthines | 1991 |
Changes caused by ethanol intake on metabolism of hypouricemic agents (combination of allopurinol and benzbromarone).
Topics: Adult; Alcohol Drinking; Allopurinol; Benzbromarone; Ethanol; Humans; Male; Middle Aged; Time Factors; Uric Acid | 1991 |
[Clinical studies on hyperuricemia and gout after transplantation].
Topics: Adult; Allopurinol; Analgesics; Benzbromarone; Female; Gout; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Uric Acid | 1990 |
Effect of ethanol on metabolism of the hypouricemic agents allopurinol and benzbromarone.
Topics: Adult; Allopurinol; Benzbromarone; Drug Interactions; Ethanol; Humans; Male; Middle Aged | 1990 |
[Is there a drug interaction between allopurinol and benzbromarone?].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Interactions; Humans | 1986 |
Inhibition of purine catabolism by benzbromarone in isolated rat liver cells. Comparison with allopurinol and probenecid.
Topics: Allopurinol; Animals; Benzbromarone; Benzofurans; In Vitro Techniques; Liver; Male; Probenecid; Purines; Rats; Rats, Inbred Strains; Uric Acid | 1988 |
Inhibition of ureogenesis by two hypouricemic drugs (probenecid and benzbromarone). Comparison with allopurinol.
Topics: Allopurinol; Animals; Arginine; Benzbromarone; In Vitro Techniques; Liver; Male; Probenecid; Rats; Rats, Inbred Strains; Urea; Uricosuric Agents | 1988 |
[Effect of an allopurinol/benzbromaron preparation on the composition of urine in a circadian course].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Calcium Oxalate; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Hydrogen-Ion Concentration; Kidney Calculi; Male; Uric Acid | 1987 |
Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Creatinine; Drug Interactions; Female; Half-Life; Humans; Kinetics; Male; Oxypurinol; Pyrimidines; Uric Acid | 1986 |
Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Creatinine; Drug Therapy, Combination; Glomerular Filtration Rate; Gout; Humans; Male; Middle Aged; Oxypurinol; Pyrimidines; Uric Acid | 1984 |
[Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Depression, Chemical; Diet; Erythrocytes; Female; Humans; Kidney; Male; Orotic Acid; Time Factors; Uric Acid | 1983 |
[Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
Topics: Allopurinol; Benzbromarone; Benzofurans; Drug Therapy, Combination; Fatty Liver, Alcoholic; Gout; Humans; Hypoxanthine; Hypoxanthines; Uric Acid; Xanthine; Xanthines | 1983 |
[Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
Topics: Allopurinol; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Gout; Humans; Uric Acid | 1983 |
[Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Drug Combinations; Glomerular Filtration Rate; Humans; Kinetics; Male; Oxypurinol; Pyrimidines | 1982 |
[Indications for and methods of allopurinol-benzbromarone combination therapy in the treatment of hyperuricemic metabolic disorders].
Topics: Adult; Aged; Allopurinol; Benzbromarone; Benzofurans; Drug Interactions; Drug Therapy, Combination; Gout; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phenylbutazone | 1982 |
Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Topics: Administration, Oral; Adult; Allopurinol; Benzbromarone; Benzofurans; Biological Availability; Drug Interactions; Female; Humans; Hydrochlorothiazide; Injections, Intravenous; Kinetics; Male; Oxypurinol; Time Factors | 1982 |
[Determination of benzbromarone in serum following combined therapy with allopurinol and benzbromarone (author's transl)].
Topics: Adult; Allopurinol; Benzbromarone; Benzofurans; Chromatography, High Pressure Liquid; Drug Combinations; Female; Humans; Kinetics; Male | 1981 |
[Treatment of hyperuricemia].
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Uric Acid | 1981 |
[Uric acid-induced diseases. 2. Therapy].
Topics: Allopurinol; Benzbromarone; Benzothiadiazines; Diuretics; Gout; Humans; Purines; Sodium Chloride Symporter Inhibitors; Uric Acid; Urinary Calculi | 1980 |
[The use of Allomaron in treating hyperuricemia].
Topics: Adult; Allopurinol; Arthritis, Gouty; Benzbromarone; Creatinine; Drug Combinations; Drug Evaluation; Female; Gout; Humans; Male; Middle Aged; Time Factors; Uric Acid | 1994 |
Gout due to xanthine derivatives.
Topics: Allopurinol; Aminophylline; Asthma; Benzbromarone; Bronchodilator Agents; Drug Therapy, Combination; Female; Gout; Humans; Middle Aged; Probenecid; Theophylline; Uric Acid; Uricosuric Agents | 1997 |
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
Topics: Adult; Allopurinol; Benzbromarone; Calcifediol; Calcitriol; Calcium; Gout; Gout Suppressants; Humans; Male; Middle Aged; Parathyroid Hormone; Phosphates; Reference Values; Uric Acid; Uricosuric Agents | 1998 |
How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Topics: Adolescent; Adult; Aged; Allopurinol; Benzbromarone; Creatinine; Drug Hypersensitivity; Gout; Gout Suppressants; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney Failure, Chronic; Male; Middle Aged; Purine-Pyrimidine Metabolism, Inborn Errors; Uric Acid | 1998 |
[Gout: physiopathology, diagnosis, course, treatment].
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Diagnosis, Differential; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Probenecid; Synovial Fluid; Uric Acid; Uricosuric Agents | 1998 |
[Hyperuricemia and gout--treatment].
Topics: Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Drug Therapy, Combination; Glucocorticoids; Gout; Gout Suppressants; Humans; Kidney Calculi; Kidney Diseases; Probenecid; Time Factors; Uric Acid; Uricosuric Agents | 2002 |
[Summary of the Dutch College of General Practitioners' "Gout" Standard].
Topics: Acute Disease; Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Chronic Disease; Colchicine; Gout; Gout Suppressants; Humans; Netherlands; Practice Guidelines as Topic; Recurrence; Uricosuric Agents | 2002 |
[Chronic gout. Case report of a severe course of disease].
Topics: Adult; Allopurinol; Benzbromarone; Chronic Disease; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Male; Uricosuric Agents | 2003 |
Spinal tophaceous gout mimicking a spinal tumor.
Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Benzbromarone; Diagnosis, Differential; Gout Suppressants; Humans; Hyperuricemia; Magnetic Resonance Imaging; Male; Spinal Neoplasms; Spondylitis | 2004 |
The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome; Uric Acid; Uricosuric Agents | 2004 |
Optimal management of chronic gout: attempting to render the (t)issues crystal-clear.
Topics: Allopurinol; Anti-Inflammatory Agents; Benzbromarone; Chronic Disease; Colchicine; Drug Hypersensitivity; Gout; Humans; Uric Acid; Uricosuric Agents | 2005 |
Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Gouty; Benzbromarone; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Gout Suppressants; Humans; Life Style; Middle Aged; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Time Factors; Uric Acid | 2006 |
Excellent response to the clinical treatment of tophaceous gout.
Topics: Aged; Allopurinol; Benzbromarone; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Male; Treatment Outcome; Uric Acid; Uricosuric Agents | 2007 |
[Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Oxypurinol; Retrospective Studies | 2008 |
Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Topics: Allopurinol; Benzbromarone; Cohort Studies; Creatinine; Follow-Up Studies; Gout; Humans; Hyperuricemia; Middle Aged; Proportional Hazards Models; Prospective Studies; Renal Colic; Risk Factors; Time Factors; Uric Acid; Uricosuric Agents; Urolithiasis | 2010 |
Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout.
Topics: Adult; Allopurinol; Arthrography; Benzbromarone; Finger Joint; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Uricosuric Agents | 2011 |
Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats.
Topics: Allopurinol; Animals; Aorta; Arginine; Benzbromarone; Biological Transport; Blood Pressure; Cationic Amino Acid Transporter 1; Disease Models, Animal; Hyperuricemia; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxonic Acid; Phosphorylation; Protein Kinase C-alpha; Rats; Rats, Wistar; Tyrosine; Uric Acid; Uricosuric Agents | 2011 |
Use of uric acid-lowering agents limits experimental cyclosporine nephropathy.
Topics: Allopurinol; Animals; Benzbromarone; Cell Proliferation; Cyclosporine; Enzyme Inhibitors; Fibrosis; Hyperuricemia; Immunohistochemistry; Kidney; Kidney Diseases; Male; Osteopontin; Random Allocation; Rats; Rats, Sprague-Dawley; Uric Acid; Uricosuric Agents; Vascular Endothelial Growth Factor A; Xanthine Oxidase | 2012 |
Anti-inflammatory and immunomodulatory effects of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats.
Topics: Actins; Allopurinol; Animals; Anti-Inflammatory Agents; Benzbromarone; Chemokine CCL2; Cyclopentane Monoterpenes; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucosides; Immunologic Factors; Iridoid Glycosides; Kidney; Kidney Diseases; Male; Medicine, Chinese Traditional; Pyrans; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Rubiaceae; Transcription Factor RelA; Uric Acid | 2012 |
Resolution of massive tophaceous gout with three urate-lowering drugs.
Topics: Allopurinol; Benzbromarone; Colchicine; Drug Therapy, Combination; Gout; Gout Suppressants; Humans; Male; Middle Aged; Urate Oxidase | 2013 |
[Effect of total saponin of Dioscorea on chronic hyperuricemia and expression of URAT1 in rats].
Topics: Animals; Anion Transport Proteins; Benzbromarone; Dioscorea; Gout Suppressants; Hyperuricemia; Kidney Tubules; Male; Rats; Rats, Sprague-Dawley; Saponins; Uric Acid; Xanthine Oxidase | 2013 |
Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
Topics: Adrenal Cortex Hormones; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Drug Therapy, Combination; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |
Influence of urate-lowering therapies on renal handling of uric acid.
Topics: Adult; Antihypertensive Agents; Benzbromarone; Case-Control Studies; Creatinine; Glomerular Filtration Rate; Gout; Humans; Hypertension; Kidney; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2016 |
Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
Topics: Aging; Allopurinol; Animal Feed; Animals; Apolipoproteins E; Arteriosclerosis; Benzbromarone; Diet; Gene Expression Regulation; Gout Suppressants; Hyperuricemia; Male; Mice; Mice, Knockout; Risk Factors; Uric Acid; Uricosuric Agents | 2014 |
Outcome of Treatment in Gouty Arthritis Patients: A Retrospective Study.
Topics: Alcohol Drinking; Allopurinol; Arthritis, Gouty; Benzbromarone; Female; Follow-Up Studies; Gout Suppressants; Humans; Kidney Function Tests; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; Uric Acid; Uricosuric Agents | 2015 |
Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate.
Topics: Adenine; Administration, Oral; Animals; Benzbromarone; Creatinine; Drug Synergism; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Male; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Oxonic Acid; Plant Exudates; Rats; Rats, Sprague-Dawley; Uric Acid; Xanthine Oxidase | 2015 |
[Using the whole arsenal to prevent an attack].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Febuxostat; Female; Gout; Gout Suppressants; Humans; Middle Aged; Polyethylene Glycols; Urate Oxidase | 2015 |
Allopurinol decreases serum uric acid level and intestinal glucose transporter-5 expression in rats with fructose-induced hyperuricemia.
Topics: Allopurinol; Animals; Benzbromarone; Fructose; Glucose Transporter Type 2; Glucose Transporter Type 5; Hyperuricemia; Intestinal Mucosa; Liver; Male; Rats; Uric Acid; Xanthine Oxidase | 2016 |
The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Topics: Aged; Allopurinol; Benzbromarone; Comorbidity; Exanthema; Female; Gout; Gout Suppressants; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; New Zealand; Retrospective Studies; Uric Acid; Uricosuric Agents | 2016 |
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Uric Acid | 2017 |
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republic of Korea; Uric Acid | 2018 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Taiwan; Uric Acid; Uricosuric Agents | 2018 |
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Febuxostat; Female; General Practitioners; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Medication Adherence; Middle Aged; Netherlands; Retrospective Studies; Rheumatologists; Uricosuric Agents; Young Adult | 2018 |
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prevalence; Proportional Hazards Models; Taiwan; Treatment Outcome; Uric Acid; Young Adult | 2019 |
[Simultaneous determination of allopurinol, probenecid, benzbromarone in dietary supplements by ultra high performance liquid chromatography-tandem mass spectrometry].
Topics: Allopurinol; Benzbromarone; Chromatography, High Pressure Liquid; Dietary Supplements; Probenecid; Tandem Mass Spectrometry | 2019 |
Monosodium Urate Contributes to Retinal Inflammation and Progression of Diabetic Retinopathy.
Topics: Allopurinol; Animals; Benzbromarone; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Humans; Hyperuricemia; Inflammation; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Retina; Risk Factors; Uric Acid; Vitreous Body; Xanthine Oxidase | 2019 |
Association of gout medications and risk of cataract: a population-based case-control study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Cataract; Colchicine; Databases, Factual; Female; Gout; Gout Suppressants; Humans; Logistic Models; Male; Middle Aged; National Health Programs; Risk Factors; Taiwan; Young Adult | 2019 |
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Triglycerides; Uric Acid; Uricosuric Agents | 2019 |
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; Fructose; Gout; Gout Suppressants; Humans; Male; Meat; Middle Aged; Prospective Studies; Purines; Shellfish; Tomography, X-Ray Computed; Uric Acid; Uricosuric Agents | 2020 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Recovery of Function; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Uricosuric Agents | 2019 |
Hyperuricemia Inhibition Protects SD Rats Against Fructose-Induced Obesity Hypertension Via Modulation of Inflammation and Renin-Angiotensin System in Adipose Tissue.
Topics: Adipose Tissue; Allopurinol; Animals; Benzbromarone; Diet, Carbohydrate Loading; Disease Models, Animal; Fructose; Gout Suppressants; Hypertension; Hyperuricemia; Inflammation; Male; Obesity, Abdominal; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System | 2021 |
Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation.
Topics: Adult; AMP-Activated Protein Kinases; Animals; Atherosclerosis; Benzbromarone; Biomarkers; Disease Models, Animal; Enzyme Inhibitors; Female; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammasomes; Inflammation; Inflammation Mediators; Interleukin-18; Interleukin-1beta; Leukocytes, Mononuclear; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Middle Aged; NLR Family, Pyrin Domain-Containing 3 Protein; Nuclear Factor 45 Protein; Plaque, Atherosclerotic; Reactive Oxygen Species; Receptors, LDL; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase; Young Adult | 2020 |
Repair of Bone Erosion With Effective Urate-Lowering Therapy in a Patient With Tophaceous Gout.
Topics: Benzbromarone; Bone Resorption; Enzyme Inhibitors; Gout; Humans; Male; Metatarsal Bones; Metatarsophalangeal Joint; Middle Aged; Nitriles; Osteogenesis; Osteophyte; Pyridines; Treatment Outcome; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2021 |
Developing, optimizing, and assessing a green electrophoretic method for determination of benzbromarone and allopurinol with its active metabolite in biological and pharmaceutical matrices.
Topics: Allopurinol; Benzbromarone; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Molecular Structure; Quality Control | 2021 |
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid | 2021 |
Development and greenness assessment of a stability-indicating HPLC-DAD method for simultaneous determination of allopurinol and benzbromarone.
Topics: Allopurinol; Benzbromarone; Chromatography, High Pressure Liquid; Tablets | 2021 |
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Cohort Studies; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Risk Factors | 2021 |
Hypouricemic effect of 2,4-dihydroxybenzoic acid methyl ester in hyperuricemic mice through inhibiting XOD and down-regulating URAT1.
Topics: Allopurinol; Animals; Benzbromarone; Esters; Hydroxybenzoates; Hyperuricemia; Kidney; Mice; Uric Acid; Xanthine Oxidase | 2022 |
Short-Term Hyperuricemia Leads to Structural Retinal Changes That Can be Reversed by Serum Uric Acid Lowering Agents in Mice.
Topics: Allopurinol; Angiotensin II; Animals; Benzbromarone; Hyperuricemia; Macular Degeneration; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred ICR; Uric Acid | 2022 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Insurance, Health; Japan; Risk Factors; Treatment Outcome; Uric Acid | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia.
Topics: Allopurinol; Benzbromarone; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2023 |